Sabby Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Sabby Management’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-145	Closed	-$75	–	301
2014 Q3	$75	Buy	+145	New	+$936	﹤0.01%	236

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Sabby Management's GNMX Position: Q2 2017 in Review

Sabby Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 19,888 shares — an estimated $37K sold.

Sabby Management first reported a position in GNMX in Q2 2013 and held it in 5 quarters. The position peaked at $1.63M in Q2 2013. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

Sabby Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 19,888 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $37K.
Sabby Management first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 5 quarters.
Sabby Management's Aevi Genomic Medicine Inc position peaked at $1.63M in Q2 2013.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.